BIOXCEL THERAPEUTICS INC's ticker is BTAI and the CUSIP is 09075P105. A total of 85 filers reported holding BIOXCEL THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.72 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $54,524 | -74.0% | 21,551 | -31.5% | 0.00% | – |
| Q2 2023 | $209,497 | -37.5% | 31,456 | +75.1% | 0.00% | – |
| Q1 2023 | $335,190 | +11.6% | 17,963 | +28.5% | 0.00% | – |
| Q4 2022 | $300,290 | +79.8% | 13,980 | -1.1% | 0.00% | – |
| Q3 2022 | $167,000 | -9.7% | 14,130 | +0.6% | 0.00% | – |
| Q2 2022 | $185,000 | -38.9% | 14,041 | -3.2% | 0.00% | – |
| Q1 2022 | $303,000 | +9.8% | 14,500 | +6.8% | 0.00% | – |
| Q4 2021 | $276,000 | -32.7% | 13,574 | +0.5% | 0.00% | – |
| Q3 2021 | $410,000 | +13.6% | 13,511 | +8.6% | 0.00% | – |
| Q2 2021 | $361,000 | -32.8% | 12,443 | -0.1% | 0.00% | – |
| Q1 2021 | $537,000 | -76.2% | 12,450 | -74.5% | 0.00% | -100.0% |
| Q4 2020 | $2,254,000 | -12.4% | 48,751 | -17.9% | 0.00% | -50.0% |
| Q3 2020 | $2,574,000 | +1.2% | 59,380 | +23.8% | 0.00% | 0.0% |
| Q2 2020 | $2,543,000 | – | 47,982 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| APIS CAPITAL ADVISORS, LLC | 40,000 | $836,000 | 1.01% |
| ACT CAPITAL MANAGEMENT, LLC | 20,000 | $418,000 | 0.44% |
| Knoll Capital Management, LLC | 20,000 | $418,000 | 0.26% |
| Artemis Investment Management LLP | 1,428,228 | $29,855,000 | 0.24% |
| Rubric Capital Management LP | 268,528 | $5,615,000 | 0.20% |
| Virtus ETF Advisers LLC | 7,713 | $161,000 | 0.07% |
| BOOTHBAY FUND MANAGEMENT, LLC | 107,700 | $2,252,000 | 0.05% |
| PDT Partners, LLC | 28,031 | $586,000 | 0.05% |
| AllSquare Wealth Management LLC | 3,162 | $66,000 | 0.04% |
| Hennion & Walsh Asset Management, Inc. | 35,221 | $736,000 | 0.04% |